Pharmaceutical giant GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech, alleging that the companies’ COVID-19 vaccines infringe on five of its patents related to mRNA technology. The suit, lodged on Thursday in a Delaware federal court, marks the latest development in a string of legal actions concerning the vaccines, which have amassed tens of billions of dollars in revenue.
Within the filing, GSK argues that Pfizer and BioNTech have made improper use of its patented mRNA technology – a critical component to the functionality of COVID-19 vaccines. Precise details about GSK’s patents and the alleged infringement remain undisclosed.
Pfizer and BioNTech join a growing list of companies involved in litigation over COVID-19 vaccine patents. Patents, whilst fostering innovation by protecting the proprietary rights of inventors, have ignited fierce debates during the pandemic. These legal disputes, often involving key industry players, underscore the high stakes and complex dynamics of providing world-wide vaccination coverage.
This lawsuit places Pfizer and BioNTech squarely in GSK’s crosshairs and promises to be a key point of attention in the coming months, as it carries potential implications for the distribution and production of COVID-19 vaccines. It also puts renewed focus on the role of intellectual property rights in the context of global health crises.
Further information about the lawsuit can be found at Law360.